Is rapamycin hard on the liver?
Rapamycin itself shows no measurably greater direct liver damage than alternative treatments in studies. The related drug everolimus measurably increases the chance of abnormal liver enzymes and raised blood fats.
Rapamycin itself (sirolimus) does not cause measurably more liver-specific side effects than alternative treatments in liver transplant patients with liver cancer. Direct liver damage has not emerged as a separate finding in the available studies on that group.
The closely related drug everolimus does show a clear signal. In cancer patients, the risk of a raised liver enzyme (a substance in your blood that indicates the liver is under strain) was almost three times as high as in the comparison group. The liver is therefore put under extra pressure, but that does not automatically mean serious or lasting damage. In liver transplant patients who received everolimus shortly after transplantation, blood fats also rose twice as often: 14% compared with 7%. Raised blood fats place an indirect burden on the liver over time.
The broader metabolic side of the picture is a point of attention with long-term use of rapamycin and related drugs. Long-term use increases the risk of high blood sugar and reduced sensitivity to insulin, and can even trigger type 2 diabetes. These are side effects that do not directly damage liver cells, but they do give the liver as an organ extra work over the long term, particularly in people who are already vulnerable.
On the other hand, short-term or intermittent use of rapamycin has an effect that resembles calorie restriction and can temporarily improve sensitivity to insulin, the opposite of what occurs with long-term use. This distinction between short-term and long-term use runs as a common thread through the research and is clinically relevant.
In concrete terms: rapamycin itself does not appear to cause direct liver damage in the groups studied, but everolimus measurably increases the chance of abnormal liver values. The indirect burden through raised blood sugar and blood fats with long-term use applies to the entire drug class.
This answer draws on several large overviews of trials, mainly in cancer patients and liver transplant patients. Those patient groups receive higher doses than healthy people using rapamycin for longevity purposes, which limits how directly the findings apply to everyday use. Direct liver damage as a separate outcome measure has barely been studied in the available research; what exists concerns liver enzymes and indirect metabolic effects.
Does rapamycin help people live longer in good health?
Rapamycin works in mice, but whether it also leads to a longer and healthier life in humans has not yet been demonstrated. Side effects are real, long-term data in healthy people are absent, and use outside a clinical context cannot currently be justified.
Can anyone take rapamycin?
Rapamycin is a powerful drug with serious side effects, including reduced immune function and blood sugar disturbances, and is not suitable for independent use outside medical supervision.
What do we know about rapamycin as an anti-ageing agent in humans?
Rapamycin shows measurable improvements in immune function and cellular ageing markers in people. Whether it also extends lifespan or genuinely slows ageing has not yet been demonstrated.
Will a doctor prescribe rapamycin?
Most doctors will not prescribe rapamycin to healthy people to slow ageing, simply because the evidence for doing so is still lacking. For certain rare conditions a specialist may consider it off-label, but always with a careful weighing of the risks.
Does rapamycin improve skin aging?
Topical rapamycin showed promising signs for skin ageing in a small study, but the evidence is still too thin to justify self-application.
Can rapamycin reverse or prevent grey hair?
Rapamycin shows promising effects on grey hair in cell and animal studies, but it has not been tested in people. It is too early to use it for this purpose.